Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PF-08046050 by Pfizer for Gastric Cancer: Likelihood of Approval
PF-08046050 is under clinical development by Pfizer and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...
PF-08046050 by Pfizer for Small-Cell Lung Cancer: Likelihood of Approval
PF-08046050 is under clinical development by Pfizer and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData, Phase...
PF-08046050 by Pfizer for Non-Small Cell Lung Cancer: Likelihood of Approval
PF-08046050 is under clinical development by Pfizer and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...
PF-08046050 by Pfizer for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
PF-08046050 is under clinical development by Pfizer and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to...
PF-08046050 by Pfizer for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
PF-08046050 is under clinical development by Pfizer and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
PF-08046050 by Pfizer for Metastatic Colorectal Cancer: Likelihood of Approval
PF-08046050 is under clinical development by Pfizer and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase...
PF-08046050 by Pfizer for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
PF-08046050 is under clinical development by Pfizer and currently in Phase I for Squamous Non-Small Cell Lung Cancer. According to...